Jean-Matthieu L'Orphelin (J-M L'Orphelin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Squamous Cell Carcinoma

Prognostic Factors

Top Venues

Therapeutic advances in hematology

Journal of the European Academy of Dermatology and Venereology : JEADV

This page only lists publications with an associated author ORCID identifier.

Publications

Jean-Matthieu L'Orphelin
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report. Therapeutic advances in hematology 15 (2024)
Jean-Matthieu L'Orphelin
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report. Therapeutic advances in hematology 15 (2024)
Jean-Matthieu L'Orphelin, J Cassecuel, L Kandolf, C A Harwood, P Tookey, Muhammad Hyder Junejo, Sarah Hogan, C Lebbé, Zoi Apalla, T-M Kränke, Giovanni Pellacani, D Cerasuolo, Branko Dujovic, V Del Marmol, A Forschner, Claus Garbe, V Bataille, Julia Maria Ressler, P Sollena, A Dompmartin, Ketty Peris, Brigitte Dreno, null null
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients - The European MelSkinTox study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Barbara Bailly-Caillé, Diane Kottler, Rémy Morello, Marie Lecornu, William Kao, Emmanuel Meyer, Anne Dompmartin, Jean-Matthieu L'Orphelin
Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Cancers 15 (2) (2023)
Barbara Bailly-Caillé, Diane Kottler, Rémy Morello, Marie Lecornu, William Kao, Emmanuel Meyer, Anne Dompmartin, Jean-Matthieu L'Orphelin
Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Cancers 15 (2) (2023)
Jean-Matthieu L'Orphelin, Emilie Varey, Amir Khammari, Brigitte Dreno, Anne Dompmartin
Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers 13 (19) (2021)